Raltegravir  	Raltegravir  	 NNP	B-NP
in  	in  	 IN	O
treatment  	treatment  	 NN	O
naive  	naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
Raltegravir  	Raltegravir  	 NNP	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
first  	first  	 JJ	O
integrase  	integrase  	 NNS	B-NP
inhibitor  	inhibitor  	 VBP	I-NP
approved  	approved  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
infection  	infection  	 VBD	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
superior  	superior  	 JJ	O
efficacy  	efficacy  	 NN	O
it  	it  	 PRP	O
showed  	showed  	 VBD	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
optimized  	optimized  	 VB	B-NP
backbone  	backbone  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
alone  	alone  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
harboring  	harboring  	 VBG	O
multidrug  	multidrug  	 JJ	B-NP
resistant  	resistant  	 JJ	I-NP
viruses 	viruses 	 NN	I-NP
.  	.  	 .	O
Studies  	Studies  	 NNS	O
on  	on  	 IN	O
naive  	naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
showed  	showed  	 VBD	O
comparable  	comparable  	 JJ	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
raltegravir  	raltegravir  	 NN	B-NP
and  	and  	 CC	O
efavirenz  	efavirenz  	 NNS	B-NP
and  	and  	 CC	O
just  	just  	 RB	O
recently  	recently  	 RB	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	B-NP
and  	and  	 CC	I-NP
Drug  	Drug  	 NNP	I-NP
Administration  	Administration  	 NNP	I-NP
( 	( 	 -LRB-	O
FDA 	FDA 	 NNP	B-NP
)  	)  	 -RRB-	O
approved  	approved  	 VBD	O
raltegravir  	raltegravir  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
in  	in  	 IN	O
naive  	naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
favorable  	favorable  	 JJ	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
international  	international  	 JJ	O
double-blind  	double-blind  	 JJ	B-NP
phase  	phase  	 NN	I-NP
III  	III  	 NNP	I-NP
STARTMRK  	STARTMRK  	 NNP	I-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
Additional  	Additional  	 JJ	O
interesting  	interesting  	 JJ	O
findings  	findings  	 NNS	O
were  	were  	 VBD	O
the  	the  	 DT	O
faster 	faster 	 RBR	O
,  	,  	 ,	O
and  	and  	 CC	O
not  	not  	 RB	O
yet  	yet  	 RB	O
explained 	explained 	 VBD	O
,  	,  	 ,	O
decay  	decay  	 NN	O
of  	of  	 IN	O
HIV-1  	HIV-1  	 NNP	B-NP
RNA  	RNA  	 NNP	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
higher  	higher  	 JJR	O
CD4+  	CD4+  	 NN	B-NP
cells  	cells  	 NNS	O
increase  	increase  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
raltegravir  	raltegravir  	 JJ	B-NP
group  	group  	 NN	I-NP
as  	as  	 IN	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
efavirenz  	efavirenz  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
Raltegravir  	Raltegravir  	 NNP	B-NP
is  	is  	 VBZ	O
generally  	generally  	 RB	O
well  	well  	 RB	O
tolerated  	tolerated  	 JJ	O
and  	and  	 CC	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
generally  	generally  	 RB	O
similar  	similar  	 JJ	O
in  	in  	 IN	O
raltegravir  	raltegravir  	 NN	B-NP
and  	and  	 CC	O
comparator  	comparator  	 JJ	B-NP
arms  	arms  	 NNS	I-NP
throughout  	throughout  	 IN	O
all  	all  	 DT	O
studies 	studies 	 NNS	O
.  	.  	 .	O
When  	When  	 WRB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
efavirenz 	efavirenz 	 VB	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
on  	on  	 IN	O
raltegravir  	raltegravir  	 NN	B-NP
showed  	showed  	 VBD	O
less  	less  	 JJR	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
central  	central  	 JJ	O
nervous  	nervous  	 JJ	O
system-related  	system-related  	 JJ	O
adverse  	adverse  	 JJ	O
events 	events 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
studies  	studies  	 NNS	O
on  	on  	 IN	O
experienced  	experienced  	 JJ	O
patients  	patients  	 NNS	O
higher  	higher  	 JJR	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
cancers  	cancers  	 NNS	O
was  	was  	 VBD	O
found  	found  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
raltegravir  	raltegravir  	 JJ	B-NP
arm 	arm 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
relationship  	relationship  	 NN	B-NP
with  	with  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	O
was 	was 	 VBD	O
,  	,  	 ,	O
however  	however  	 RB	O
not  	not  	 RB	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
recent  	recent  	 JJ	O
review  	review  	 NN	O
considering  	considering  	 VBG	O
all  	all  	 DT	O
raltegravir  	raltegravir  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Raltegravir  	Raltegravir  	 NNP	B-NP
also  	also  	 RB	O
showed  	showed  	 VBD	O
a  	a  	 DT	O
safe  	safe  	 JJ	O
lipid  	lipid  	 JJ	B-NP
profile  	profile  	 NN	I-NP
especially  	especially  	 RB	O
in  	in  	 IN	O
naive  	naive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
finding  	finding  	 VBG	O
that  	that  	 IN	O
renders  	renders  	 VBG	O
the  	the  	 DT	O
drug  	drug  	 NN	O
attractive  	attractive  	 JJ	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
other  	other  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
factors 	factors 	 NNS	I-NP
.  	.  	 .	O
All  	All  	 PDT	O
this  	this  	 DT	O
characteristics  	characteristics  	 NN	O
in  	in  	 IN	O
association  	association  	 NN	O
with  	with  	 IN	O
its  	its  	 PRP$	O
specific  	specific  	 JJ	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action 	action 	 NN	O
,  	,  	 ,	O
make  	make  	 VBP	O
raltegravir  	raltegravir  	 VBG	O
an  	an  	 DT	O
interesting  	interesting  	 JJ	O
drug  	drug  	 NN	O
for  	for  	 IN	O
naive  	naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
large  	large  	 JJ	O
use  	use  	 NN	O
in  	in  	 IN	O
this  	this  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
is  	is  	 VBZ	O
predictable 	predictable 	 JJ	O
.  	.  	 .	O
Only  	Only  	 JJ	B-NP
time  	time  	 NN	I-NP
and  	and  	 CC	O
experience 	experience 	 NN	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
will  	will  	 MD	O
tell  	tell  	 VB	O
us  	us  	 PRP	O
whether  	whether  	 IN	O
raltegravir  	raltegravir  	 NNS	B-NP
will  	will  	 MD	O
maintain  	maintain  	 VB	O
its  	its  	 PRP$	O
promises  	promises  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
long  	long  	 JJ	O
run 	run 	 NN	O
.  	.  	 .	O
